Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Losoxantrone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 10/20 | 0.98 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.50 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.50 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.50 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.50 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.50 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.50 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.50 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.50 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.50 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.50 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.50 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.50 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.50 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.50 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.50 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.50 |
| ▸ | CACNA1S known ✓ | Q13698 | 1/20 | 0.50 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Losoxantrone SCHEMBL6685621 | 1.00 | TOP2A (0.98) | TOP2AMEN1USP2LMNATP53 | |
| Losoxantrone SCHEMBL5170 | 0.99 | TOP2A (0.96) | TOP2AMEN1USP2LMNATP53 | |
| Losoxantrone SCHEMBL61319 | 0.99 | TOP2A (1.00) | TOP2AMEN1USP2LMNATP53 | |
| Losoxantrone SCHEMBL29360703 | 0.99 | TOP2A (1.00) | TOP2AMEN1USP2LMNATP53 | |
| Losoxantrone SCHEMBL27927741 | 0.96 | TOP2A (0.94) | TOP2AMEN1USP2LMNATP53 | |
| SCHEMBL10800466 | 0.94 | TOP2A (0.90) | TOP2AMEN1USP2LMNATP53 | |
| Losoxantrone SCHEMBL27975856 | 0.93 | TOP2A (0.88) | TOP2AMEN1USP2LMNATP53 | |
| SCHEMBL22877226 | 0.92 | TOP2A (0.87) | TOP2AMEN1USP2LMNATP53 | |
| SCHEMBL18689529 | 0.92 | TOP2A (0.87) | TOP2AMEN1USP2LMNATP53 | |
| SCHEMBL10805434 | 0.91 | TOP2A (0.86) | TOP2AMEN1USP2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4649173-A1 | METHOD OF PROFILING DISEASES | Akrivia Biomedics Limited (GB) | 2025-11-19 | — | — | EP | disclosed |
| WO-2025233437-A1 | POLYPEPTIDE COMPRISING A CAPSID PROTEIN SEQUENCE | A-SPECTAR GMBH (AT) | 2025-11-13 | — | — | WO | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-20240285793-A1 | TOBACCO MOSAIC VIRUS DELIVERY OF MITOXANTRONE FOR CANCER THERAPY | UNIV CASE WESTERN RESERVE (US) | 2024-08-29 | — | — | US | disclosed |
| WO-2024150017-A1 | METHOD OF PROFILING DISEASES | AKRIVIA BIOMEDICS LIMITED (GB) | 2024-07-18 | — | — | WO | disclosed |
| US-20230220063-A1 | IL-1BETA BINDING ANTIBODIES FOR USE IN TREATING CANCER | NOVARTIS PHARMACEUTICALS CORPORATION | 2023-07-13 | — | — | US | disclosed |
| US-20230088070-A1 | USE OF IL-1BETA BINDING ANTIBODIES | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| US-20220389090-A1 | USE OF IL-1BETA BINDING ANTIBODIES | NOVARTIS PHARMACEUTICALS CORPORATION | 2022-12-08 | — | — | US | disclosed |
| US-20220056123-A1 | USE OF IL-1BETA BINDING ANTIBODIES | NOVARTIS AG (CH) | 2022-02-24 | — | — | US | disclosed |
| US-20220025036-A1 | USE OF IL-1BETA BINDING ANTIBODIES | NOVARTIS AG (CH) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056123-A1 | USE OF IL-1BETA BINDING ANTIBODIES | IL1B, IL1RN, IL1A | TOP2A 3618/4885CACNA1F 785/4885EGFR 2706/4885 |
| US-20230088070-A1 | USE OF IL-1BETA BINDING ANTIBODIES | IL1B, IL1RN, IL1A | TOP2A 4257/4885CACNA1F 643/4885EGFR 3800/4885 |
| US-20220025036-A1 | USE OF IL-1BETA BINDING ANTIBODIES | IL1B, IL1RN, IL1A | TOP2A 3825/4885CACNA1F 487/4885EGFR 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.